Medline Q3 2026 slides: sales rise 10%, shares jump 15% on guidance

Medline reported Q3 2026 net sales of $7.9 billion, up 10.4%, and adjusted EBITDA of $960 million, up 11.8%; shares rose 15.58% to $39.40 after the results and the company’s first $1 billion share-repurchase authorization. Medline raised 2026 organic sales growth guidance to 10.0%-10.5% while maintaining adjusted EBITDA guidance of $3.3 billion-$3.4 billion. Supply Chain Solutions sales grew 13.9%, but segment adjusted EBITDA fell 10.2% to $184 million amid customer-mix and cost pressures; management expects 2027 sales growth in the high single digits and EBITDA growth in the low-to-mid single digits.

Analysis

The key underwriting issue is earnings quality, not demand: tariff refunds flatter current profitability while Supply Chain Solutions’ growth is diluting segment EBITDA. If new Prime Vendor contracts do not convert into Medline-brand penetration and productivity, the company could compound revenue while missing the margin recovery embedded in the longer-term narrative. That creates an opening for incumbent distributors to defend accounts with pricing or service rather than ceding profitable business.

The 15.6% post-results jump likely brings forward some of the good news. The $1bn authorization may support sentiment, but it is not a commitment to repurchase and competes with capacity and quality spending for capital. For 2027, slower EBITDA than sales growth is a meaningful near-term valuation constraint; tariff favorability is conditional, and durable cost inflation or remediation needs could extend the margin trough. Conversely, evidence that new accounts are converting to higher-margin own-brand products would validate the investment cycle and support earnings re-acceleration beyond 2027.

Time frame: immediate—gap-up risk/reward is less attractive; 1–3 months—watch for contract implementation and underlying margin evidence; 6–18 months—judge whether brand conversion and productivity offset operating, quality, and input-cost burdens. No valuation or consensus data are provided, so avoid a price target or claiming the shares are expensive.

Key Decisions for Investors

• Do not chase the initial gap. For existing holders, consider trimming into strength or holding only against a defined review of underlying EBITDA; the buyback authorization alone is not a floor.
• Use the next quarterly reports as a catalyst check: track Supply Chain Solutions EBITDA against sales growth, Medline Brand conversion within new Prime Vendor accounts, and results excluding tariff-refund benefits. Improving margins despite growth investments would falsify the cautious near-term thesis.
• Keep MDLN on a conditional long watchlist rather than initiate immediately. Reassess after evidence of contract cohorts converting to own-brand sales and productivity gains; a further deterioration in segment EBITDA or weaker 2027 guidance would argue against the recovery case.
• Monitor tariff policy, diesel and raw-material costs, and Global Quality Action Plan spending. Persistent cost increases without timely pricing recovery—or additional remediation requirements—would raise downside risk; stable costs and measurable conversion would improve the 6–18 month setup.